About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
PMID: 37745192 Journal: JHEP Reports Year: 2023 Reference: JHEP Rep. 2023 Jul 13;5(10):100842. doi: 10.1016/j.jhepr.2023.100842. eCollection 2023 Oct. Impact factor: Publication type: Paper in international publication Authors: Berg, Thomas; Bes, Marta; Buti, Maria; Buti, Maria; Casillas, Rosario; Esteban, Rafael; Esteban, Rafael; Esteban, Rafael; Palom, Adriana; Pfefferkorn, Maria et al. DOI: 10.1016/j.jhepr.2023.100842
PMID: 37760489 Journal: Cancers Year: 2023 Reference: Cancers (Basel). 2023 Sep 12;15(18):4520. doi: 10.3390/cancers15184520. Impact factor: Publication type: Paper in international publication Authors: Clar-Marmaneu, Helena; Garcia-Fernandez, Alba Estela; Garcia-Fernandez, Francisco Javier et al. DOI: 10.3390/cancers15184520
PMID: 37802652 Journal: SEXUALLY TRANSMITTED INFECTIONS Year: 2023 Reference: Sex Transm Infect. 2023 Oct 6:sextrans-2023-055899. doi: 10.1136/sextrans-2023-055899. Impact factor: Publication type: Paper in international publication Authors: Alvarez-Lopez, Patricia; Alvarez-Lopez, Patricia; Arando, Maider; Arando, Maider; Blanco-Grau, Albert; Curran, Adrian; Curran, Adrian; Descalzo, Vicente; El Ouazzani, Rachid; Garcia, Jorge Nestor et al. DOI: 10.1136/sextrans-2023-055899
PMID: 37808908 Journal: Frontiers in Cellular and Infection Microbiology Year: 2023 Reference: Front Cell Infect Microbiol. 2023 Sep 21;13:1175996. doi: 10.3389/fcimb.2023.1175996. eCollection 2023. Impact factor: Publication type: Review in international publication Authors: Quer, Josep; Rando-Segura, Ariadna; Rodriguez-Frias, Francisco et al. DOI: 10.3389/fcimb.2023.1175996
PMID: 35124196 Journal: SEMINARS IN CANCER BIOLOGY Year: 2022 Reference: Semin Cancer Biol. 2022 Nov;86(Pt 3):431-444. doi: 10.1016/j.semcancer.2022.01.010. Epub 2022 Feb 3. Impact factor: Publication type: Paper in international publication Authors: Garcia-Mayea, Y; Kondoh, H; LLeonart, M E; Mir, C; Paciucci, R; Zhao, Y et al. DOI: 10.1016/j.semcancer.2022.01.010
PMID: 35089571 Journal: Methods in molecular biology (Clifton, N.J.) Year: 2022 Reference: Methods Mol Biol. 2022;2406:401-416. doi: 10.1007/978-1-0716-1859-2_24. Impact factor: Publication type: Paper in international publication Authors: Aris, Anna; Cano-Garrido, Olivia; Garcia-Fruitos, Elena; Peternel, Spela; Seras-Franzoso, Joaquin et al. DOI: 10.1007/978-1-0716-1859-2_24
PMID: 34229512 Journal: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM Year: 2022 Reference: J Cereb Blood Flow Metab. 2022 Feb;42(2):237-252. doi: 10.1177/0271678X211028816. Epub 2021 Jul 6. Impact factor: Publication type: Paper in international publication Authors: Arrue, Mercedes; Belloli, Sara; Castellote, Laura; Garcia-Gabilondo, Miguel; Grayston, Alba; Kopcansky, Peter; Kovac, Jozef; Martin, Abraham; Moresco, Rosa M; Picchio, Maria et al. DOI: 10.1177/0271678X211028816
PMID: 35053290 Journal: Biomolecules Year: 2022 Reference: Biomolecules. 2022 Jan 16;12(1). pii: biom12010143. doi: 10.3390/biom12010143. Impact factor: Publication type: Review in international publication Authors: Jacobs-Cacha, Conxita; Llorens-Cebria, Carmen; Molina-Van den Bosch, Mireia; Soler, Maria Jose; Vergara, Ander et al. DOI: 10.3390/biom12010143
PMID: 33880971 Journal: EXPERT REVIEW OF MOLECULAR DIAGNOSTICS Year: 2021 Reference: Expert Rev Mol Diagn. 2021 Apr;21(4):381-396. doi: 10.1080/14737159.2021.1913055. Epub 2021 Apr 21. Impact factor: Publication type: Review in international publication Authors: Buti, Maria; Cortese, Maria Francesca; Garcia-Garcia, Selene; Quer, Josep; Rando-Segura, Ariadna; Rodriguez-Algarra, Francisco; Rodriguez-Frias, Francisco; Tabernero, David et al. DOI: 10.1080/14737159.2021.1913055
PMID: 33314628 Journal: Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology Year: 2021 Reference: Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 May;13(3):e1684. doi: 10.1002/wnan.1684. Epub 2020 Dec 13. Impact factor: Publication type: Review in international publication Authors: Abasolo, Ibane; Corchero, Jose Luis; Diaz-Riascos, Vanessa; Molto-Abad, Marc; Pintos-Morell, Guillem; Schwartz, Simo Jr; Seras-Franzoso, Joaquin et al. DOI: 10.1002/wnan.1684
PMID: 33278456 Journal: JOURNAL OF HEPATOLOGY Year: 2021 Reference: J Hepatol. 2021 May;74(5):1064-1074. doi: 10.1016/j.jhep.2020.11.043. Epub 2020 Dec 2. Impact factor: Publication type: Paper in international publication Authors: Bartres, Concepcion; Forns, Xavier; Garcia-Lopez, Mireia; Garcia-Pras, Ester; Koutsoudakis, George; Lens, Sabela; Leonel, Thais; Lozano, Juan Jose; Maini, Mala K; Marino, Zoe et al. DOI: 10.1016/j.jhep.2020.11.043
PMID: 32663522 Journal: Clinical Gastroenterology and Hepatology Year: 2021 Reference: Clin Gastroenterol Hepatol. 2021 May;19(5):1030-1037. doi: 10.1016/j.cgh.2020.07.006. Epub 2020 Jul 11. Impact factor: Publication type: Paper in international publication Authors: Buti, M; Esteban, R; Llaneras, J; Marcos-Fosch, C; Rando-Segura, A; Riveiro-Barciela, M; Roade, L; Rodriguez-Frias, F; Velazquez, F et al. DOI: 10.1016/j.cgh.2020.07.006
PMID: 31908952 Journal: Molecular Genetics and Metabolism Reports Year: 2020 Reference: Mol Genet Metab Rep. 2020 Jan 2;22:100553. doi: 10.1016/j.ymgmr.2019.100553. eCollection 2020 Mar. Impact factor: Publication type: Paper in international publication Authors: Argudo-Ramirez, A; Arranz, J A; Casellas, M D; Del Toro, M; Fernandez, R; Garcia-Villoria, J; Gonzalez de Aledo-Castillo, J M; Gort, L; Lopez, R M; Marin, J L et al. DOI: 10.1016/j.ymgmr.2019.100553
PMID: 32143211 Journal: PLoS One Year: 2020 Reference: PLoS One. 2020 Mar 6;15(3):e0230022. doi: 10.1371/journal.pone.0230022. eCollection 2020. Impact factor: Publication type: Paper in international publication Authors: Alsina, Merce; Conesa, Jose Javier; Gil, Silvia; Kamma-Lorger, Christina; Martinez-Esain, Jordi; Martinez-Trucharte, Francesc; Perez-Berna, Ana J; Sabes, Manel; Solano, Eduardo et al. DOI: 10.1371/journal.pone.0230022
Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.
Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.
Researchers from all over Europe gathered to kick off the SPM4.0 project, an innovative Marie Curie Skłodowska (MSCA-DN) doctoral network that promotes the development of autonomous Scanning Probe Microscopy with AI.
